Comorbidities in Dermatology

Dermatologic Clinics

Volumn 27, Issue 2, 2009, Pages 137-147

  Wakkee, Marlies ^a   Nijsten, Tamar ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Atopic dermatitis; Comorbidities; Epidemiology; Non melanoma skin cancer; Psoriasis; Vitiligo

Indexed keywords

ACICLOVIR; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIPSORIASIS AGENT; COAL TAR; CORTICOSTEROID; CYCLOSPORIN; DIGOXIN; METHOTREXATE; PSORALEN; VITAMIN D;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALCOHOL CONSUMPTION; ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; COMORBIDITY; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; DRUG CARCINOGENICITY; DRUG MEGADOSE; ENTERITIS; GENETIC LINKAGE; GLIOMA; HERPES SIMPLEX; HUMAN; INFECTION RISK; LIFESTYLE; LYMPHOMA; MENTAL DISEASE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; QUALITY OF LIFE; REVIEW; RISK FACTOR; SECONDARY INFECTION; SIDE EFFECT; SKIN CANCER; SMOKING HABIT; SQUAMOUS CELL CARCINOMA; STAPHYLOCOCCUS INFECTION; STREPTOCOCCAL PHARYNGITIS; TUBERCULOSIS; VACCINATION; VIRUS INFECTION; VITAMIN INTAKE; VITILIGO;

CHRONIC DISEASE; COMORBIDITY; DERMATOLOGY; HUMANS; SKIN DISEASES;

EID: 60849107597     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2008.11.013     Document Type: Review

References (111)

1. Feinstein A. The pretherapeutic classification of comorbidity in chronic disease. J Chronic Dis 23 (1970) 455-468
2. Wikipedia. Comorbidity. Available at:. http://en.wikipedia.org/wiki/Comorbidity Last accessed 29 September 2008
3. Chen T., Bertenthal D., Sahay A., et al. Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. Arch Dermatol 143 (2007) 1386-1392
4. Christophers E. Comorbidities in psoriasis. Clin Dermatol 25 (2007) 529-534
5. Gelfand J.M., Gladman D.D., Mease P.J., et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 53 (2005) 573-577
6. Moll J.M., and Wright V. Psoriatic arthritis. Semin Arthritis Rheum 3 (1973) 55-78
7. Taylor W., Gladman D., Helliwell P., et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54 (2006) 2665-2673
8. Finzi A.F., and Gibelli E. Psoriatic arthritis. Int J Dermatol 30 (1991) 1-7
9. Rahman P., Gladman D.D., Cook R.J., et al. Radiological assessment in psoriatic arthritis. Br J Rheumatol 37 (1998) 760-765
10. Gladman D.D., Mease P.J., Ritchlin C.T., et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 56 (2007) 476-488
11. Kavanaugh A.F., and Ritchlin C.T. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 33 (2006) 1417-1421
12. Krueger G., and Ellis C.N. Psoriasis-recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 53 (2005) S94-S100
13. Wakkee M., Thio H.B., Prens E.P., et al. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 190 (2007) 1-9
14. McDonald C.J., and Calabresi P. Occlusive vascular disease in psoriatic patients. N Engl J Med 288 (1973) 912
15. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 172 (1986) 298-304
16. Stern R.S., and Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J Invest Dermatol 91 (1988) 197-201
17. Mallbris L., Akre O., Granath F., et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 19 (2004) 225-230
18. Sommer D.M., Jenisch S., Suchan M., et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 298 (2006) 321-328
19. Gisondi P., Tessari G., Conti A., et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 157 (2007) 68-73
20. Gelfand J.M., Neimann A.L., Shin D.B., et al. Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006) 1735-1741
21. Kaye J.A., Li L., Jick S.S., et al. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 159 (2008) 895-902
22. Neimann A.L., Shin D.B., Wang X., et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55 (2006) 829-835
23. Setty A.R., Curhan G., Choi H.K., et al. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 167 (2007) 1670-1675
24. Naldi L., Chatenoud L., Linder D., et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125 (2005) 61-67
25. Brauchli Y.B., Jick S.S., Curtin F., et al. Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study. Br J Dermatol 158 (2008) 1299-1307
26. Wakkee M., van der Linden M., Nijsten T., et al. Psoriasis appears not to be directly related with using cardiovascular and antidiabetic drugs. J Invest Dermatol 128 (2008) 1299-1307
27. Kimball A.B., Gladman D., Gelfand J.M., et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 58 (2008) 1031-1042
28. Margolis D., Bilker W., Hennessy S., et al. The risk of malignancy associated with psoriasis. Arch Dermatol 137 (2001) 778-783
29. Frentz G., and Olsen J.H. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 140 (1999) 237-242
30. Boffetta P., Gridley G., Lindelof B., et al. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 117 (2001) 1531-1537
31. Marcil I., and Stern R.S. Squamous-cell cancer of the skin in patients given PUVA and cyclosporine: nested cohort crossover study. Lancet 358 (2001) 1042-1045
32. Stern R.S. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 44 (2001) 755-761
33. Roelofzen J.H., Aben K.K., van der Valk P.G., et al. Coal tar in dermatology. J Dermatolog Treat 18 (2007) 329-334
34. Naldi L., Parazzini F., Brevi A., et al. Family history, smoking habits, alcohol consumption and risk of psoriasis. Br J Dermatol 127 (1992) 212-217
35. Poikolainen K., Reunala T., Karvonen J., et al. Alcohol intake: a risk factor for psoriasis in young and middle aged men?. BMJ 300 (1990) 780-783
36. Gelfand J.M., Berlin J., Van Voorhees A., et al. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 139 (2003) 1425-1429
37. Gelfand J.M., Shin D.B., Neimann A.L., et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 126 (2006) 2194-2201
38. Stern R.S. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol 142 (2006) 1132-1135
39. Paul C.F., Ho V.C., McGeown C., et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 120 (2003) 211-216
40. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
41. Norrlind R. The significance of infections in the origination of psoriasis. Acta Rheumatol Scand 1 (1955) 135-144
42. Gudjonsson J.E., Thorarinsson A.M., Sigurgeirsson B., et al. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br J Dermatol 149 (2003) 530-534
43. Tomi N.S., Kranke B., Aberer E., et al. Staphylococcal toxins in patients with psoriasis, atopic dermatitis, and erythroderma, and in healthy control subjects. J Am Acad Dermatol 53 (2005) 67-72
44. Henseler T., and Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 32 (1995) 982-986
45. Harder J., Bartels J., Christophers E., et al. A peptide antibiotic from human skin. Nature 387 (1997) 861
46. Lande R., Gregorio J., Facchinetti V., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449 (2007) 564-569
47. Hollox E.J., Huffmeier U., Zeeuwen P.L., et al. Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 40 (2008) 23-25
48. Drancourt M., Argenson J.N., Tissot Dupont H., et al. Psoriasis is a risk factor for hip-prosthesis infection. Eur J Epidemiol 13 (1997) 205-207
49. Sadick N.S., McNutt N.S., Kaplan M.H., et al. Papulosquamous dermatoses of AIDS. J Am Acad Dermatol 22 (1990) 1270-1277
50. Patel R.V., and Weinberg J.M. Psoriasis in the patient with human immunodeficiency virus, part 1: review of pathogenesis. Cutis 82 (2008) 117-122
51. Zhang X.J., Zhang A.P., Yang S., et al. Association of HLA class I alleles with psoriasis vulgaris in southeastern Chinese Hans. J Dermatol Sci 33 (2003) 1-6
52. Goh B.K., Chan R.K., Sen P., et al. Spectrum of skin disorders in human immunodeficiency virus-infected patients in Singapore and the relationship to CD4 lymphocyte counts. Int J Dermatol 46 (2007) 695-699
53. Smith J.D., and Knox J.M. Psoriasis, methotrexate and tuberculosis. Br J Dermatol 84 (1971) 590-593
54. Vachharajani T.J., Oza U.G., Phadke A.G., et al. Tuberculosis in renal transplant recipients: rifampicin sparing treatment protocol. Int Urol Nephrol 34 (2002) 551-553
55. Kroesen S., Widmer A.F., Tyndall A., et al. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 42 (2003) 617-621
56. Lebwohl M., Bagel J., Gelfand J.M., et al. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 58 (2008) 94-105
57. Lee F.I., Bellary S.V., Francis C., et al. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 85 (1990) 962-963
58. Kia K.F., Nair R.P., Ike R.W., et al. Prevalence of antigliadin antibodies in patients with psoriasis is not elevated compared with controls. Am J Clin Dermatol 8 (2007) 301-305
59. Michaelsson G., Gerden B., Ottosson M., et al. Patients with psoriasis often have increased serum levels of IgA antibodies to gliadin. Br J Dermatol 129 (1993) 667-673
60. Damasiewicz-Bodzek A., and Wielkoszynski T. Serologic markers of celiac disease in psoriatic patients. J Eur Acad Dermatol Venereol 22 (2008) 1055-1061
61. Dreiher J., Weitzman D., Shapiro J., et al. Psoriasis and chronic obstructive pulmonary disease: a case-control study. Br J Dermatol 159 (2008) 956-960
62. Spergel J.M., and Paller A.S. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 112 (2003) S118-S127
63. Burrows B., Martinez F.D., Halonen M., et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 320 (1989) 271-277
64. Wuthrich B. Serum IgE in atopic dermatitis: relationship to severity of cutaneous involvement and course of disease as well as coexistence of atopic respiratory diseases. Clin Allergy 8 (1978) 241-248
65. Eichenfield L.F., Hanifin J.M., Beck L.A., et al. Atopic dermatitis and asthma: parallels in the evolution of treatment. Pediatrics 111 (2003) 608-616
66. Kondo H., Ichikawa Y., Imokawa G., et al. Percutaneous sensitization with allergens through barrier-disrupted skin elicits a Th2-dominant cytokine response. Eur J Immunol 28 (1998) 769-779
67. Warner J.O. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up. J Allergy Clin Immunol 108 (2001) 929-937
68. Bustos G.J., Bustos D., Bustos G.J., et al. Prevention of asthma with ketotifen in preasthmatic children: a three-year follow-up study. Clin Exp Allergy 25 (1995) 568-573
69. Cole G.W., and Silverberg N.L. The adherence of staphylococcus aureus to human corneocytes. Arch Dermatol 122 (1986) 166-169
70. Ong P.Y., Ohtake T., Brandt C., et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347 (2002) 1151-1160
71. Zeeuwen P.L., de Jongh G.J., Rodijk-Olthuis D., et al. Genetically programmed differences in epidermal host defense between psoriasis and atopic dermatitis patients. PLoS ONE 3 (2008) e2301
72. Birnie A.J., Bath-Hextall F., Ravenscroft J.C., et al. Interventions to reduce staphylococcus aureus in the management of atopic eczema. Cochrane Database Syst Rev 3 (2008) CD003871
73. Lin Y.T., Wang C.T., Chiang B.L., et al. Role of bacterial pathogens in atopic dermatitis. Clin Rev Allergy Immunol 33 (2007) 167-177
74. Wollenberg A., and Klein E. Current aspects of innate and adaptive immunity in atopic dermatitis. Clin Rev Allergy Immunol 33 (2007) 35-44
75. Yoon M., and Spear P.G. Disruption of adherens junctions liberates nectin-1 to serve as receptor for herpes simplex virus and pseudorabies virus entry. J Virol 76 (2002) 7203-7208
76. Linos E., Raine T., Alonso A., et al. Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst 99 (2007) 1544-1550
77. Wen W., Shu X.O., Linet M.S., et al. Allergic disorders and the risk of childhood acute lymphoblastic leukemia (United States). Cancer Causes Control 11 (2000) 303-307
78. Spector L., Groves F., DeStefano F., et al. Medically recorded allergies and the risk of childhood acute lymphoblastic leukaemia. Eur J Cancer 40 (2004) 579-584
79. Schuz J., Morgan G., Bohler E., et al. Atopic disease and childhood acute lymphoblastic leukemia. Int J Cancer 105 (2003) 255-260
80. Wang H., and Diepgen T.L. Is atopy a protective or a risk factor for cancer? A review of epidemiological studies. Allergy 60 (2005) 1098-1111
81. Alkhateeb A., Fain P.R., Thody A., et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 16 (2003) 208-214
82. Shong Y.K., and Kim J.A. Vitiligo in autoimmune thyroid disease. Thyroid 3 (1991) 89-91
83. Schallreuter K.U., Lemke R., Brandt O., et al. Vitiligo and other diseases: coexistence or true association? Hamburg study on 321 patients. Dermatology 188 (1994) 269-275
84. Amerio P., Tracanna M., De Remigis P., et al. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3B+C and 4. Clin Exp Dermatol 31 (2006) 746-749
85. Dittmar M., and Kahaly G.J. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab 88 (2003) 2983-2992
86. Canaris G.J., Manowitz N.R., Mayor G., et al. The Colorado thyroid disease prevalence study. Arch Intern Med 160 (2000) 526-534
87. Hollowell J.G., Staehling N.W., Flanders W.D., et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87 (2002) 489-499
88. Jin Y., Mailloux C.M., Gowan K., et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 356 (2007) 1216-1225
89. Soerjomataram I., Louwman W.J., Lemmens V.E., et al. Are patients with skin cancer at lower risk of developing colorectal or breast cancer?. Am J Epidemiol 167 (2008) 1421-1429
90. Jensen A.O., Bautz A., Olesen A.B., et al. Mortality in Danish patients with nonmelanoma skin cancer, 1978-2001. Br J Dermatol 159 (2008) 419-425
91. Hunter D.J., Colditz G.A., Stampfer M.J., et al. Diet and risk of basal cell carcinoma of the skin in a prospective cohort of women. Ann Epidemiol 2 (1992) 231-239
92. Han J., Colditz G.A., Hunter D.J., et al. Polymorphisms in the MTHFR and VDR genes and skin cancer risk. Carcinogenesis 28 (2007) 390-397
93. Li C., Liu Z., Zhang Z., et al. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol 127 (2007) 276-280
94. Bikle D.D. Vitamin D receptor, UVR, and skin cancer: a potential protective mechanism. J Invest Dermatol 128 (2008) 2357-2361
95. Holick MF. McCollum Award Lecture, 1994: vitamin D-new horizons for the 21st century. Am J Clin Nutr 1994;60:619-30.
96. Cotterill J.A., and Cunliffe W.J. Suicide in dermatological patients. Br J Dermatol 137 (1997) 246-250
97. Fried R.G., Gupta M.A., Gupta A.K., et al. Depression and skin disease. Dermatol Clin 23 (2005) 657-664
98. Sampogna F., Picardi A., Chren M.M., et al. Association between poorer quality of life and psychiatric morbidity in patients with different dermatological conditions. Psychosom Med 66 (2004) 620-624
99. Both H., Essink-Bot M.L., Busschbach J., et al. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol 127 (2007) 2726-2739
100. Rapp S.R., Feldman S.R., Exum M.L., et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41 (1999) 401-407
101. Sharma N., Koranne R.V., Singh R.K., et al. Psychiatric morbidity in psoriasis and vitiligo: a comparative study. J Dermatol 28 (2001) 419-423
102. Esposito M., Saraceno R., Giunta A., et al. An Italian study on psoriasis and depression. Dermatology 212 (2006) 123-127
103. Akay A., Pekcanlar A., Bozdag K.E., et al. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J Eur Acad Dermatol Venereol 16 (2002) 347-352
104. Gupta M.A., Gupta A.K., Watteel G.N., et al. Early onset (< 40 years age) psoriasis is comorbid with greater psychopathology than late onset psoriasis: a study of 137 patients. Acta Derm Venereol 76 (1996) 464-466
105. Gupta M.A., Gupta A.K., Kirkby S., et al. Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. Arch Dermatol 124 (1988) 1052-1057
106. Ahmar H., and Kurban A.K. Psychological profile of patients with atopic dermatitis. Br J Dermatol 95 (1976) 373-377
107. Linnet J., and Jemec G.B. An assessment of anxiety and dermatology life quality in patients with atopic dermatitis. Br J Dermatol 140 (1999) 268-272
108. Hashiro M., and Okumura M. Anxiety, depression and psychosomatic symptoms in patients with atopic dermatitis: comparison with normal controls and among groups of different degrees of severity. J Dermatol Sci 14 (1997) 63-67
109. Gupta M.A., Gupta A.K., Schork N.J., et al. Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosom Med 56 (1994) 36-40
110. Himmerich H., Fulda S., Linseisen J., et al. Depression, comorbidities and the TNF-alpha system. Eur Psychiatry 23 (2008) 421-429
111. Tyring S., Gottlieb A., Papp K., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367 (2006) 29-35